#1 Clinical Trials Search in Europe

(4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One

This article discusses clinical trials investigating (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One, a radioactive imaging agent used in brain scans. The trials aim to evaluate how this substance can help measure synaptic density (the number of connections between brain cells) in patients with Alzheimer’s disease, and how it relates to tau protein buildup in the brain.

Table of Contents

Overview of the Imaging Agent

(4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One is a specialized radioactive imaging agent also known as [18F]SynVesT-1[1]. This substance is designed to help doctors and researchers visualize and measure synaptic density in the human brain using advanced imaging techniques[1]. Synapses are the connection points between brain cells where information is transmitted, and their density reflects the overall health and function of brain networks.

The imaging agent contains a radioactive fluorine-18 isotope, which allows it to be detected by PET (Positron Emission Tomography) scanners[1]. When administered to patients, (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One binds to specific proteins found in synapses, creating a map of where brain cell connections are located and how abundant they are in different brain regions.

Understanding Alzheimer’s Disease and Brain Imaging

Alzheimer’s disease is a progressive brain disorder that affects memory, thinking, and behavior[1]. One of the key features of Alzheimer’s disease is the loss of synapses, which leads to reduced communication between brain cells. Scientists believe that measuring synaptic density could provide important information about disease progression and help evaluate potential treatments.

In addition to synaptic loss, Alzheimer’s disease is characterized by the accumulation of abnormal proteins in the brain[1]. One of these proteins is called tau, which forms tangles inside brain cells and contributes to their dysfunction and death. The clinical trial investigating (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One aims to understand the relationship between synaptic loss and tau pathology.

Current brain imaging techniques can detect tau protein using another imaging agent called [18F]flortaucipir[1]. By using both (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One and [18F]flortaucipir in the same patients, researchers can create a comprehensive picture of brain changes in Alzheimer’s disease.

Trial Design and Objectives

The clinical trial investigating (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One is a Phase 2 interventional study that has been authorized to proceed[1]. Phase 2 trials are designed to evaluate whether a diagnostic tool or treatment works effectively in a larger group of patients while continuing to monitor safety.

The primary objective of this trial is to quantify brain regional uptake of (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One, which reflects synaptic density in different areas of the brain[1]. The study will also measure [18F]flortaucipir uptake to assess tau pathology and examine the association between these two measurements.

Key features of the trial design include:

  • Study type: Interventional, meaning participants will receive the imaging agent as part of the research protocol[1]
  • Target enrollment: Approximately 30 participants with Alzheimer’s disease[1]
  • Current status: Authorized and preparing to begin enrollment[1]
  • Trial identifier: 2024-517636-22-00[1]

Who Can Participate

The trial is designed for individuals who have been diagnosed with Alzheimer’s disease[1]. The study plans to enroll 30 participants who will undergo brain imaging with both (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One and [18F]flortaucipir.

While specific eligibility criteria are not detailed in the available trial information, typical requirements for Alzheimer’s disease imaging studies may include:

  • Confirmed diagnosis of Alzheimer’s disease based on clinical and cognitive assessments
  • Ability to undergo PET scanning procedures
  • Willingness to participate in research and provide informed consent
  • Absence of conditions that would interfere with brain imaging

Potential participants should contact the research team conducting the trial to learn about specific eligibility requirements and the enrollment process.

What the Trial Measures

The trial will use advanced brain imaging techniques to measure two key aspects of Alzheimer’s disease pathology[1]. Understanding what researchers are measuring helps clarify how this study contributes to Alzheimer’s disease research.

Synaptic Density Measurement

The primary measurement involves quantifying how much (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One accumulates in different brain regions[1]. This brain regional uptake reflects the density of synapses in each area. Researchers will analyze:

  • The overall amount of synaptic density across the brain
  • Differences in synaptic density between brain regions
  • Patterns of synaptic loss that may correlate with disease severity
  • How synaptic density relates to clinical symptoms and cognitive function

Tau Pathology Assessment

Participants will also receive [18F]flortaucipir PET scans to measure tau protein accumulation in the brain[1]. This allows researchers to:

  • Identify brain regions with high tau protein deposits
  • Quantify the extent of tau pathology
  • Compare tau distribution with synaptic density patterns

Association Analysis

A critical aspect of the trial is examining the association between synaptic density and tau pathology[1]. Researchers will analyze whether areas with more tau accumulation show greater synaptic loss, which could provide insights into how Alzheimer’s disease damages brain connections.

Clinical Significance

This trial investigating (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One represents an important advance in Alzheimer’s disease research[1]. The ability to measure synaptic density in living patients could transform how doctors diagnose and monitor the disease.

Currently, most Alzheimer’s disease diagnosis relies on cognitive testing and imaging techniques that detect brain shrinkage or protein deposits. However, synaptic loss is thought to be more directly related to cognitive symptoms than these other markers. If (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One proves effective, it could:

  • Enable earlier detection of Alzheimer’s disease before significant symptoms appear
  • Provide a more precise way to track disease progression
  • Help evaluate whether new treatments protect or restore brain connections
  • Improve understanding of the relationship between different pathological processes in Alzheimer’s disease

The Phase 2 status of this trial indicates that preliminary research has already shown promise, and this larger study will provide more comprehensive data about the imaging agent’s performance[1]. The results could support the development of (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One as a standard diagnostic tool for Alzheimer’s disease.

By enrolling 30 participants, the study will generate sufficient data to assess the reliability and clinical utility of synaptic density imaging[1]. This sample size allows researchers to detect meaningful patterns and relationships between synaptic loss, tau pathology, and clinical features of Alzheimer’s disease.

Trial ID Phase Condition Studied Status Enrollment Study Type
2024-517636-22-00 Phase 2 Alzheimer’s disease Authorised 30 Interventional

FAQ

  • What is (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One being studied for? This substance, also known as [18F]SynVesT-1, is being studied as an imaging agent to measure synaptic density in the brains of patients with Alzheimer's disease. Researchers want to understand how the loss of brain cell connections relates to tau protein accumulation.
  • Who can participate in these clinical trials? The current trial is enrolling approximately 30 participants with Alzheimer's disease. Specific eligibility criteria would be determined by the research team conducting the study.
  • What phase are these clinical trials in? The trial investigating (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One is in Phase 2, which focuses on evaluating the effectiveness and safety of the imaging agent in a larger group of patients.
  • What is the main goal of these trials? The primary goal is to quantify brain regional uptake of (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One to measure synaptic density and determine its association with tau protein pathology in Alzheimer's disease patients.
  • What type of study is being conducted? This is an interventional study, meaning participants will receive the imaging agent (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One during brain scans to help researchers measure and understand brain changes in Alzheimer's disease.

Ongoing Clinical Trials on (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One

  • A study comparing [18F]SynVesT-1 and [18F]flortaucipir to measure synaptic density and tau protein levels in patients with Alzheimer’s disease

    Recruiting

    1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Synaptic density: The number of synapses (connections between brain cells) in a specific brain region. Higher synaptic density indicates more brain cell connections, while lower density suggests loss of connections, which occurs in Alzheimer's disease.
  • Tau pathology: The abnormal accumulation and tangling of tau proteins inside brain cells, which is one of the hallmark features of Alzheimer's disease and contributes to brain cell death.
  • Phase 2 trial: A stage of clinical research that tests whether a treatment or diagnostic tool works effectively in a larger group of patients and continues to evaluate its safety.
  • Interventional study: A type of clinical trial where researchers give participants a specific treatment, medication, or diagnostic test to study its effects, rather than just observing them.
  • [18F]flortaucipir: A radioactive imaging agent used in PET scans to detect and measure tau protein deposits in the brain, helping to diagnose and track Alzheimer's disease progression.
  • Brain regional uptake: The amount of an imaging agent that accumulates in different areas of the brain, which helps researchers see which brain regions are affected by disease.
  • Radioactive imaging agent: A substance containing a small amount of radioactive material that is used in medical scans to create images of the inside of the body or brain.
  • PET scan: Positron Emission Tomography, a medical imaging technique that uses radioactive tracers to create detailed pictures of organs and tissues, often used to study brain function and disease.

References

  1. https://clinicaltrials.gov/study/2024-517636-22-00